|
KMID : 0363220190570010009
|
|
Korean Journal of Dermatology
2019 Volume.57 No. 1 p.9 ~ p.14
|
|
|
Efficacy and Safety of Secukinumab for the Treatment of Moderate to Severe Psoriasis in Korea
|
|
Ha Dae-Lyong
Kim Woo-Il
Yang Min-Young
Lee Won-Ku
Kim Tae-Wook
Park Sung-Min
Lee Hyun-Joo
Kim Gun-Wook
Kim Hoon-Soo
Ko Hyun-Chang
Kim Moon-Bum
Kim Moon-Bum
Kim Byung-Soo
|
|
|
Abstract
|
|
|
Background: Secukinumab, a fully human monoclonal antibody that targets interleukin (IL)-17A, which is a central cytokine in the pathogenesis of psoriasis, has emerged as a promising treatment for moderate to severe psoriasis.
However, to date, there are no real-world data for secukinumab in Korean patients with psoriasis.
Objective: To assess the clinical efficacy and safety of secukinumab in Korean patients with psoriasis.
Methods: Prospective data were gathered during follow-up from 28 consecutive patients with chronic plaque-type psoriasis treated with secukinumab for minimum of 12 weeks at a single referral center. Patient demographics, Psoriasis Area Severity Index (PASI) score, Physicians’ Global Assessment (PGA), Dermatologic Life Quality Index (DLQI), and adverse events were investigated.
Results: The mean PASI score was significantly decreased after the induction period of secukinumab treatment (paired t-test, p<0.05). Of the 28 patients, 17 (60.7%) had obtained near complete clearance (PASI 90) at the last follow-up visit. No unexpected adverse events, other than nasopharyngitis, were observed.
Conclusion: Secukinumab can be of benefit for the treatment of Korean patients with psoriasis, as the treatment was associated with a rapid and satisfactory response and safety profile.
|
|
|
KEYWORD
|
|
|
Clinical setting, Efficacy, Psoriasis, Safety, Secukinumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|